LOGO.png
Autolus Therapeutics Reports First Quarter 2021 Financial Results and Operational Progress
May 06, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, May 06, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call on May 6
April 26, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, April 26, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics Receives Innovation Passport and entry into ILAP for AUTO4 for the treatment of T cell receptor constant region beta chain 1 (TRBC1) positive T cell lymphomas
April 20, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics announces appointment of Martin Murphy as Non-executive Chairman
April 19, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, April 19, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics to Participate in Investor Conferences Through April
April 01, 2021 16:01 ET | Autolus Therapeutics plc
LONDON, April 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics Receives PRIME designation for AUTO1 for the treatment of adult ALL
April 01, 2021 08:45 ET | Autolus Therapeutics plc
LONDON, April 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics Announces Updated Manufacturing Facility Strategy Leveraging its UK Operations
March 29, 2021 08:00 ET | Autolus Therapeutics plc
- Autolus to expand on existing operations in the UK for commercial supply of AUTO1 resulting in a less capital-intensive commercial infrastructure strategy- Mutual agreement to terminate lease for...
LOGO.png
Autolus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Progress
March 04, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, March 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
February 24, 2021 07:00 ET | Autolus Therapeutics plc
LONDON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
LOGO.png
Autolus Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional ADSs
February 12, 2021 16:01 ET | Autolus Therapeutics plc
LONDON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...